N60.3
Fibrosclerosis of breast
Clinical Classification Guidelines
Inclusion Terms
- Cystic mastopathy with epithelial proliferation
Medical Intelligence & Overview
Fibrosclerosis of the breast, classified under ICD-10 code N60.3, is a benign condition characterized by the thickening and hardening of breast tissue due to excessive fibrosis and scarring. Often associated with cystic mastopathy, this condition involves cyst formation alongside epithelial proliferation, leading to changes in the breast's structure and appearance. Though not cancerous, its symptoms can resemble those of more serious conditions, making accurate diagnosis and understanding essential for appropriate management.
Causes & Symptoms
Clinical Causes: Hormonal fluctuations, particularly involving estrogen and progesterone Chronic inflammation or recurring cystic changes within breast tissue Epithelial proliferation resulting from hormonal or other cellular stimuli Genetic predisposition to fibrous tissue growth Previous breast trauma or surgical procedures Lifestyle factors such as smoking or poor nutrition that may influence tissue health
Key Symptoms: Lumps or nodules within the breast tissue that may be tender or painful Diffuse, firm, and irregular thickening of the breast tissue Breast tenderness or discomfort, especially before menstrual periods Changes in the texture or density of the breast upon physical examination Presence of cystic formations that can sometimes be felt or detected via imaging No significant change in the size of the breast but noticeable alterations in consistency
Diagnostic & Treatment
Diagnosis Path: The assessment of fibrosclerosis of the breast typically involves a combination of clinical examination and imaging techniques. Diagnostic steps include: - Detailed patient history to identify symptoms and potential causes - Physical breast examination to detect lumps, thickening, or tenderness - Imaging studies such as mammography or ultrasound to visualize cystic structures and fibrous tissue - Fine-needle aspiration or biopsy when necessary to exclude malignancy and confirm epithelial proliferation Laboratory tests are generally not specific but may be performed to evaluate hormonal levels or rule out other conditions.
Treatment Protocols: Management of fibrosclerosis of the breast focuses on alleviating symptoms and monitoring the condition. Treatment options are often conservative and may include: - Symptomatic relief through analgesics or anti-inflammatory medications - Hormonal therapy in select cases, aimed at balancing hormonal influences - Regular follow-up with imaging to monitor tissue changes over time - Lifestyle modifications such as maintaining a healthy diet, avoiding caffeine or alcohol if advised by a healthcare professional - Surgical intervention is rarely necessary but may be considered if cysts or fibrous tissue cause significant discomfort or suspicion of malignancy It is important for patients to consult healthcare providers for personalized management plans and to distinguish benign fibrosclerosis from other breast conditions requiring different interventions.
Clinical Advice & FAQs
Billing Guidance
Is N60.3 a billable ICD-10 code?
Yes, N60.3 is a specific, billable code that can be used to indicate a diagnosis for reimbursement purposes.
Documentation
How do I report N60.3?
Clinical documentation must specify the nature of Fibrosclerosis of breast and any associated comorbidities for accurate reporting.
Cite this Clinical Reference
